Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Peter Selin | Chief Executive Officer | 2.62M | -- | 1973 |
Dr. Thomas Olin Ph.D. | Executive VP & Director | 3.45M | -- | 1958 |
Mr. Hans Richter | Chief Financial Officer | -- | -- | 1949 |
Dr. Robert Edfors | Chief Medical Officer | -- | -- | -- |
Kancera AB (publ)
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 5
Description
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Corporate Governance
Upcoming Events
May 23, 2025 at 10:59 AM UTC
Kancera AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available